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Frontotemporal lobar degeneration (FTLD) is the most common cause of dementia with
pre-senile onset, accounting for asmany as 20%of cases.A common subset of FTLD cases
is characterized by the presence of ubiquitinated inclusions in vulnerable neurons (FTLD-U).
While the pathophysiological mechanisms underlying neurodegeneration in FTLD-U have
not yet been elucidated, the presence of inclusions in this disease indicates enhanced
aggregation of one or several proteins. Moreover, these inclusions suggest altered expres-
sion, processing, or degradation of proteins during FTLD-U pathogenesis. Thus, one
approach to understanding disease mechanisms is to delineate the molecular changes in
protein composition in FTLD-Ubrain. Using a combined approach consisting of laser capture
microdissection (LCM) and high-resolution liquid chromatography-tandemmass spectrom-
etry (LC–MS/MS), we identiﬁed 1252 proteins in hippocampal dentate granule cells excised
from three post-mortem FTLD-U and three unaffected control cases processed in par-
allel. Additionally, we employed a labeling-free quantiﬁcation technique to compare the
abundance of the identiﬁed proteins between FTLD-U and control cases. Quantiﬁcation
revealed 54 proteins with selective enrichment in FTLD-U, including TAR–DNA binding
protein 43 (TDP-43), a recently identiﬁed component of ubiquitinated inclusions. More-
over, 19 proteinswere selectively decreased in FTLD-U. Subsequent immunohistochemical
analysis of TDP-43 and three additional protein candidates suggests that our proteomic
proﬁling of FTLD-U dentate granule cells reveals both inclusion-associated proteins and
non-aggregated disease-speciﬁc proteins. Application of LCM is a valuable tool in the mol-
ecular analysis of complex tissues, and its application in the proteomic characterization of
neurodegenerative disorders such as FTLD-U may be used to identify proteins altered in
disease.
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INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a progressive neu-
rologic disorder that manifests profound behavioral, personality,
and language symptoms (Neary et al., 2005; Kumar-Singh and
Van Broeckhoven, 2007). In the past few decades, the pathologic
classiﬁcation of FTLD has been primarily accomplished using bio-
chemical and immunohistochemical approaches to differentiate
the composition of proteinaceous aggregates found in the brain.
Historically, three major neuropathological subtypes have been
identiﬁed in FTLD, including tauopathies, FTLD cases lacking dis-
tinctive histopathology, and FTLD-ubiquitinated (FTLD-U) type
(Woulfe et al., 2001). Recent studies have suggested that FTLD-U
is the most common of these subtypes, accounting for approxi-
mately half of all FTLD cases (Graff-Radford andWoodruff, 2007;
Snowden et al., 2007). The histopathologic hallmark of FTLD-U
is the presence of ubiquitin-positive, tau and α-synuclein-negative
intraneuronal inclusions primarily in the hippocampal dentate
gyrus and frontotemporal cortex (Kovari et al., 2004). Interest-
ingly, a similar pathology is also seen in cases of FTLD-U with
concomitant motor neuron disease (MND), which suggests that
FTLD-U and MND share a common pathogenesis (Forman et al.,
2006).
Pathological lesions inmanyneurodegenerative diseases exhibit
ubiquitin immunoreactivity, reﬂecting common downstream cel-
lular responses to protein complexes.However, the identities of the
inciting proteins that aggregate differ depending on the particular
disease. In FTLD-U inclusions, the primary protein constituents
have proven difﬁcult to characterize, hampering understanding of
key early events in the disease pathogenesis. This obstacle has been
primarily technical in nature, as the small size and distribution of
the inclusions precluded the application of biochemical puriﬁca-
tion and identiﬁcation approaches common in the study of other
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pathologic lesions. In fact, it was only recently that the ﬁrst non-
ubiquitin components of FTLD-U inclusions were identiﬁed as
TAR–DNA-Binding Protein 43 (TDP-43; Neumann et al., 2006)
and Fused in Sarcoma (FUS; Kwiatkowski et al., 2009; Vance et al.,
2009), both nuclear RNA binding proteins involved in RNA splic-
ing and transcriptional regulation (Yang et al., 1998; Buratti et al.,
2001; Tan and Manley, 2010).
The identiﬁcation of TDP-43 as a primary aggregating protein
in FTLD-U has fueled efforts to further deﬁne the mechanisms
leading to protein aggregation, inclusion formation, and neurode-
generation in this disorder. To date, however, limited progress has
been made in the characterization of additional functionally rele-
vant proteins in sporadic FTLD-U. In contrast, several genes have
been associated with the pathogenesis of familial disease forms
(Rollinson et al., 2009), including the discovery of pathogenic
mutations in the progranulin gene (GRN ; Baker et al., 2006; Cruts
et al., 2006), valosin-containing protein (VCP) on chromosome
9p21 (Watts et al., 2004), and charged multivesicular body pro-
tein 2B (CHMP2B) on chromosome 3p11 (Skibinski et al., 2005).
GRN mutations cause a loss-of-function (haploinsufﬁciency) by
introducing premature termination codons ormissensemutations
that result in rapid mRNA degradation or non-functional pro-
tein expression (Baker et al., 2006; Eriksen and Mackenzie, 2008).
Thus, unlike TDP-43, mutations in GRN do not result in the
accumulation of aggregated progranulin. Similarly, neither VCP
nor CHMP2B have been shown to systematically accumulate in
theubiquitin-immunoreactive neuropathology.Notably, extensive
histopathological characterization of familial and sporadic FTLD-
U cases reveals differences in aggregate distribution, density, and
morphology, suggesting that they may not share a common mol-
ecular basis (Mackenzie and Rademakers, 2007). As such, further
molecular analysis of sporadic FTLD-U tissues is warranted.
The development of laser capturemicrodissection (LCM) tech-
nology over the past 15 years (Emmert-Buck et al., 1996) has
given investigators a new method to isolate and study neurode-
generative disease tissues. LCM is a rapid, reliable method for the
isolation of speciﬁc cells, or small biologically relevant areas, from
complex tissues (Emmert-Buck et al., 1996). Using a low-power
laser to melt a thermoplastic ﬁlm onto a tissue section, a target of
interest as small as 3–5μm in diameter can be isolated (Bonner
et al., 1997). Multiple laser shots can be combined on the same
ﬁlm in order to procure cell clusters or more complicated tissue
structures (Simone et al., 1998). Importantly, the remarkable pre-
cision demonstrated in the laser capture process, coupled with
minimal direct handling and processing of the captured mater-
ial, reduces contamination in collected samples andminimizes the
impact on downstream analyses (Ornstein et al., 2000). However,
the process of LCM allows the recovery of only a minimal amount
of protein from captured tissues, a limitation that may be largely
addressed by the application of high-sensitivity proteomics plat-
forms such as liquid chromatography – tandemmass spectrometry
(LC–MS/MS).
The combination of LCM and LC–MS/MS offers a unique
opportunity to study neurodegenerative disorders because these
diseases are characterized by the presence of selectively vulnerable
populations of neurons (Morrison et al., 1998) and by dis-
tinct neuropathological lesions that can be microdissected and
analyzed. For example, we have previously applied this com-
bined approach in the characterization of senile plaques from
post-mortem Alzheimer’s disease (AD) brain tissues (Liao et al.,
2004; Gozal et al., 2006). Speciﬁcally, we demonstrated the co-
isolation of 488 proteins with the plaques, including more than
80% of the previously documented plaque proteins. More sig-
niﬁcantly, quantitative comparison of plaques and non-plaque
tissues revealed at least 2-fold enrichment of 26 proteins in the
plaque regions, an indication of the complexity and diversity of
cellular processes involved in the formation of plaques. Thus,
in this study, we coupled LCM and LC–MS/MS to identify and
quantitate proteins isolated from neurons containing ubiquiti-
nated inclusions in the hippocampal dentate gyrus of FTLD-U
patients. We reveal signiﬁcant changes in 73 proteins in FTLD-U
compared with unaffected controls, and evaluate the potential of
this approach for proﬁling protein expression in cells that speciﬁ-
cally accumulate ubiquitin-immunoreactive inclusions and other
complex aggregates in neurodegeneration.
MATERIALS AND METHODS
CASE MATERIAL
All cases used in these studies were obtained from the Alzheimer’s
Disease Research Center (ADRC) and Center for Neurodegener-
ative Disease (CND) Brain Bank at Emory University School of
Medicine. The inclusion of FTLD-U cases was based on extensive
neuropathologic characterization required for diagnosis based on
consensus criteria (McKhann et al., 2001; Trojanowski and Dick-
son, 2001; Cairns et al., 2007). All cases exhibited small, ubiquitin-
positive, tau andα-synuclein-negativeneuronal cytoplasmic inclu-
sions in the hippocampal dentate gyrus. Additionally, these cases
did notmeet criteria for neuropathological diagnosis of AD (Mirra
et al., 1991; The National Institute on Aging, and Reagan Institute
Working Group on Diagnostic Criteria for the Neuropathologi-
cal Assessment of Alzheimer’s Disease, 1997), Lewy body disease
(McKeith et al., 2005), or tau pathology consistent with a tauopa-
thy (Litvan et al., 1996; Dickson, 1998). TDP-43 immunoreactivity
was histochemically conﬁrmed in all FTLD-U cases. Control cases
had neither a clinical history nor a neuropathologic diagnosis of
neurologic disease, and were selected to match FTLD-U cases in
post-mortem interval (PMI) to prevent signiﬁcant variability in
protein quality. Samples were separated into three independent
FTLD-U/Control comparisons for processing and analysis.
ANTIBODIES
Commercially available primary antibodies used in these stud-
ies were to the proteins TDP-43 (rabbit polyclonal; Protein Tech
Group, Chicago, IL, USA), septin 3 (goat polyclonal; Abcam,
Cambridge, MA, USA), septin 7 (rabbit polyclonal; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), glial ﬁbrillary acidic pro-
tein (GFAP; mouse monoclonal; DAKO, Carpinteria, CA, USA),
and ubiquitin (rabbit polyclonal; DAKO).
PREPARATION OF TISSUES FOR LCM
Isolation of hippocampal dentate gyrus granule cells by
LCM was performed based on previously developed protocols
(Emmert-Buck et al., 1996; Goldsworthy et al., 1999). Ethanol-
ﬁxed, parafﬁn-embedded 10μm-thick hippocampal sections
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mounted on uncoated and uncharged glass slides were deparaf-
ﬁnized in xylene and rehydrated. Sections were subsequently
stained for 1min inHistogene Staining Solution (Arcturus,Moun-
tain View, CA, USA), differentiated in 75% ethanol for 1min,
subjected to dehydration in graded alcohols, cleared for 5min
in fresh xylene, and air-dried for 5min. Finally, sections were
desiccated prior to LCM (Emmert-Buck et al., 1996).
LASER CAPTURE MICRODISSECTION
Laser capture microdissection was performed using a Pixcell II
laser capture system (Arcturus). Hippocampal dentate granule
cells were visualized and captured with short-duration pulses
(1ms) of an infrared laser (laser spot size: 7.5μm) using a laser
power setting of 80–90mW. Typically, granule cells of the dentate
gyrus from three to four consecutive sections (10μm thick) were
captured on a single CapSure Macro LCM cap (Arcturus), and
50–60 sections were processed from each individual.
PROTEIN EXTRACTION FROM LCM CAPS
Protein extractionswere performed as previously described (Gozal
et al., 2006). Brieﬂy, caps were extracted for 15min at 65˚C with
20μl of lysis buffer composed of 2% sodium dodecyl sulfate
(SDS), 10%glycerol, 10mMdithiothreitol (DTT), 1mMethylene-
diaminetetraacetic acid (EDTA), and protease inhibitor cocktail
(PIC; Roche Applied Science) in phosphate-buffered saline, pH
7.2. The caps were then re-extracted for 15min at 65˚C with a
fresh 20μl aliquot of lysis buffer. The lysis buffer was reused in
the sequential extractions of up to four caps containing captured
hippocampal dentate gyri from the same case. The procedure
was repeated until all caps corresponding to a particular case
were extracted, and the extracts were then pooled to produce
one extracted sample for each case. To normalize total proteins
submitted for proteomic analysis, protein concentration was esti-
mated from a modiﬁed silver staining (Shevchenko et al., 1996) of
5% of the sample as previously described (Gozal et al., 2006).
ANALYSIS AND PROTEIN IDENTIFICATION BY MASS SPECTROMETRY
Mass spectrometric analysis and protein identiﬁcation was per-
formed as described previously (Liao et al., 2004; Gozal et al.,
2009). Brieﬂy, samples were ﬁrst separated on a 10% SDS gel
(0.75mm thickness), and visualized with Coomassie Blue G-250.
Sample lanes were cut into 6 gel bands and digested with trypsin.
The resulting digested peptides were extracted from each of the gel
pieces and analyzed by LC–MS/MS using a hybrid LTQ–FT linear
ion trap/7-T Fourier transform ion cyclotron resonance (FT-
ICR) mass spectrometer (Thermo Electron, San Jose, CA, USA).
The acquired MS/MS spectra were searched against the human
reference database (29,575 proteins) of the National Center for
Biotechnology Information (January 2007) using the SEQUEST-
Sorcerer algorithm version 3.11 r11 (Sage-N-Research, San Jose,
CA, USA; Eng et al., 1994). A target-decoy ﬁltering strategy was
subsequently used to evaluate the peptide identiﬁcation false dis-
covery rate (Peng et al., 2003). False positive matches were thus
ﬁltered out ﬁrst by mass accuracy (15 ppm) and then by dynam-
ically increasing XCorr (minimal 1.8) and ΔCn (minimal 0.05)
values such that the false discovery rate was less than 0.2%. Gener-
ally, following manual validation of the spectra (Peng et al., 2003),
we accepted proteins identiﬁed by at least one unique peptide.
LABEL-FREE QUANTIFICATION: EXTRACTED ION CURRENT
Quantiﬁcation of proteins in the LCM extracts was based on the
comparison of paired peptides within each of the three inde-
pendent FTLD-U/Control comparisons as previously described
(Gozal et al., 2009). Ion current intensities for identiﬁed peptides
were extracted in MS survey scans, and a ratio of the peak inten-
sities for the peptide precursor ion was calculated. The resultant
ratio was used as a measure of the relative abundance of the pep-
tide within each FTLD-U/control comparison (Wang et al., 2003).
Abundance ratios for all peptides of a particular protein were aver-
aged to determine the protein abundance ratio. To evaluate the
statistical signiﬁcance of the protein changes, a histogram of all
protein abundance ratios after logarithmic transformation (log2)
was ﬁtted to a Gaussian distribution according to the null hypoth-
esis. Proteins identiﬁed and consistently reduced or enriched in at
least two of the independent FTLD-U/Control comparisons with
log2 ratios fallingmore than twoSD from themeanof theGaussian
distribution were marked as signiﬁcantly altered.
IMMUNOHISTOCHEMISTRY
Free-ﬂoating 50μm-thick frontal cortex and hippocampus
sections from 6 FTLD-U and six control cases were incubated
with 3%hydrogen peroxide (H2O2) to quench endogenous perox-
idase activity, blocked in normal serum, and incubated overnight
at 4˚C with primary antibody. Sections were then incubated
with a biotinylated secondary antibody and signal was visual-
ized using an avidin–biotin–peroxidase complex method (Vector
Elite ABC Kit, Vector Laboratories, Burlingame, CA, USA) with
3,3′-diaminobenzidine (DAB) as a chromogen.
WESTERN BLOTTING
Post-mortem frontal cortex from AD, FTLD-U, or control cases
was extracted at 5mL/g (volume/weight) with ice-cold low salt
(LS) buffer (10mM Tris, pH 7.5, 5mM EDTA, 1mM DTT, 10%
sucrose, 10mM β-glycerophosphate, 10mM sodium orthovana-
date, 10mMtetrasodiumpyrophosphate, 50mMsodiumﬂuoride,
1× Roche complete PIC). The resulting homogenate was diluted
in an equal volume of 2× RIPA buffer (100mM Tris•Cl pH 7.3,
300mM sodium chloride, 2mM EDTA, 2% Triton-X-100, 2%
deoxycholate, and 0.2% SDS) with 1× Roche complete PIC and
10mM iodoacetic acid (IAA). Samples were sonicated on ice and
centrifuged at 25,000× g for 15min at 4˚C. The RIPA soluble
extract (supernatant) was collected and the pellet (insoluble frac-
tion) was subsequently incubated in 20μL of 8M urea in SDS
loading buffer (63mM Tris HCl, 10% Glycerol, 2% SDS, 0.0025%
Bromophenol Blue, 5% 2-Mercaptoethanol, 1× PIC, and 10mM
IAA) prior to trituration and sonication. Immunoblotting was
performed according to standard procedures as described previ-
ously (Seyfried et al., 2010) with either 25μg of insoluble fraction
or 60μg of RIPA soluble fraction.
RESULTS
IDENTIFICATION OF PROTEINS IN FTLD-U DENTATE GRANULE CELLS BY
LC–MS/MS
Using LCM, we selectively dissected the granule cell layer of the
dentate gyrus, a site of abundant pathologic inclusions in FTLD-U,
from three clinically and pathologically conﬁrmed FTLD-U cases
www.frontiersin.org April 2011 | Volume 2 | Article 24 | 3
Gozal et al. LCM in proteomics of FTLD-U
and three unaffected controls for proteomic analysis (Table 1).
Each FTLD-U case was paired with a control case after match-
ing for gender and PMI (±6 h) in order to minimize variation
due to other variables. To collect sufﬁcient material for pro-
teomics, the maximum number of granule cells from each dentate
gyrus were captured (Figures 1A,B) from 50 to 60 ethanol-ﬁxed,
parafﬁn-embedded, post-mortem hippocampal sections per case,
requiring 3000–5000 laser pulses per section. Protein captured
from each case was subsequently extracted with SDS, separated
by mass using SDS gel electrophoresis, and quantiﬁed to estimate
Table 1 | Demographic information.
Comparisons Diagnosis Age at onset (years) Age at death (years) Duration (years) Gender (male/female) PMI (h)
Comparison 1 FTLD-U 56 64 8 F 6
Control 74 0 F 7
Comparison 2 FTLD-U 56 61 5 M 17.5
Control 61 0 M <12
Comparison 3 FTLD-U 62 71 9 F 18
Control 57 0 F 17
FIGURE 1 | Dissection and preparation of LCM samples for proteomics.
(A) Before and (B) after images depicting efﬁcient removal of the hippocampal
dentate gyrus via LCM. (C) Representative silver stain of extracted proteins
captured from one FTLD-U case and one unaffected control. Proteins were
extracted using SDS-containing lysis buffer, and a small fraction of each
sample (∼5%) was separated by SDS-PAGE and examined by silver staining.
The remainder of each sample (∼95%) was resolved on a separate SDS gel
and stained with Coomassie Blue G-250. Each sample lane was then cut into
six pieces according to the molecular weight marker as is shown on the
right.
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total protein yield by silver stain (Figure 1C). For each case,∼5μg
of total protein was collected by LCM of hippocampal sections,
thus requiring that the samples be analyzed byMS in their entirety
and precluding the processing of a replicate sample. Moreover,
while the total protein analyzed was controlled for each FTLD-U
and control pair, signiﬁcant variations in the amount of ana-
lyzed protein may have been present between paired comparisons
in order to maximize the number of proteins identiﬁed in each
case. Following the division of the samples into three independent
FTLD-U/control comparisons, the extracted proteins were sepa-
rated on a second SDS gel. Each gel lane was subsequently cut
into six pieces by molecular weight, and exposed to in-gel diges-
tion with trypsin. The resultant tryptic peptides were analyzed by
high-resolution LC–MS/MS, the method of choice for large-scale
proteomics. The spectra acquired for each sample were searched
against a human protein database, and further ﬁltered by mass
accuracy and matching scores. We identiﬁed 6694 peptides cor-
responding to 1252 proteins across the three paired case/control
comparisons. Of these, 218 proteins were found in all three paired
comparisons (Figure 2).
RELATIVE QUANTIFICATION OF IDENTIFIED PROTEINS BY A
LABEL-FREE STRATEGY
Quantitation of protein changes between FTLD-U and control
dentate granule cell proteomes was based on the ratio of the
extracted ion currents of peptides identiﬁed in each case. Abun-
dance ratios (FTLD-U/Control) corresponding to the relative pro-
tein abundance between the FTLD-U and control proteomes were
calculated for all of the peptides obtained in this experiment. To
evaluate the signiﬁcance of the protein changes and to correct
the quantitative errors resulting from sample handling and/or
ionization instability, the abundance ratios for all 1252 proteins
identiﬁed in this experiment were averaged over the three com-
parisons, transformed into log2 (ratio), and plotted as shown in
Figure 3 (Li et al., 2003; Cheng et al., 2006). Because the majority
FIGURE 2 | Identification of proteins in independent FTLD-U/Control
comparisons. Proteins identiﬁed in each comparison are represented by
colored circles. The number of overlapped proteins between comparisons is
indicated in the relevant areas. A total of 1252 proteins were identiﬁed
across all three FTLD-U/Control comparisons. Of these, 218 were
independently identiﬁed in each of the three comparisons.
FIGURE 3 | Distribution of abundance ratios reveals a subset of
altered FTLD-U proteins. Logarithmic (base 2) transformation of
protein ratios from FTLD-U/control comparisons was performed and
plotted with each point corresponding to the number of proteins in
each 0.25 unit window (solid black line). A normal distribution was
subsequently ﬁtted to the data (red line) and used to determine the
two SD threshold used in ﬁltering (dotted black line). Total
proteins= 1252.
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of proteins tend to display similar abundance in diseased and
control tissues, the resultant experimental distribution was ﬁtted
to a normal distribution on the basis of the central limit theorem.
Using thenormal distributionparameters,we identiﬁed signiﬁcant
enrichment (≥2 SD from the mean) of 54 proteins in FTLD-U
dentate granule cells comparedwith control.Moreover,19proteins
were found tobe signiﬁcantly reduced inFTLD-Ucases. In order to
increase the reliability of the dataset, we considered only proteins
detected in at least two out of three FTLD-U/Control comparisons
(518 proteins). Finally, only the proteins demonstrating consis-
tency in the direction of the measured change (i.e., enriched in all
comparisons) were included in this ﬁnal list (Tables 2 and 3).
ANALYSIS OF SELECTED FTLD-U ENRICHED COMPONENTS
Our quantitative comparison of proteins captured by LCM iden-
tiﬁes a list of candidate molecules that might play a signiﬁcant
role in FTLD-U pathogenesis. Immunohistochemical staining for
TDP-43 revealed abundant labeled inclusions in the FTLD-U
dentate granule cells (Figure 4A) while the controls showed no
labeling. The identiﬁcation of TDP-43, a well-established disease
protein known to associatewithFTLD-Upathological lesions, sub-
stantiates the sensitivity of our proteomic strategy and validates
our use of LCM samples in proteomics analyses. However, while
TDP-43 was among the proteins meeting these ﬁltering restric-
tions, it showed only a moderate ∼1.5 fold increase in FTLD-U.
Several additional candidate proteins were selected for immuno-
histochemical (IHC) analysis based on the availability of speciﬁc
antibodies and themagnitude of enrichment in FTLD-U. IHCwas
performed in frontal cortex and hippocampal sections from six
additional post-mortemFTLD-U cases and six unaffected controls
using antibodies to ubiquitin (Figure 4B), septin 3 (Figure 4C),
septin 7 (Figure 4D), and GFAP (data not shown). These antibod-
ies did not reveal associations with inclusions or staining overlap
with ubiquitin immunoreactivity in the cases studied, suggest-
ing that many of the enriched proteins identiﬁed through our
LCM and LC–MS/MS approach represent soluble proteins rather
than components of insoluble aggregates. To further examine the
relationship of septin 3 and septin 7 with insoluble aggregates
in FTLD-U, we performed immunoblot analysis on biochemi-
cally extracted FTLD-U,AD, and control frontal cortex (Figure 5).
Interestingly,while detergent-insoluble urea samples didnot reveal
enrichment of either protein, septin 3was noted to be up-regulated
in detergent-soluble fractions. Thus, while enriched in FTLD-
U tissues, neither protein appears to comprise the pathologic
aggregates in this disorder.
DISCUSSION
The complete composition of inclusions and the mechanisms
underlying their formation in neurodegeneration are currently
unclear. The evaluation of pathological inclusions in FTLD-U
and other diseases has, to date, been based on conventional neu-
ropathologic approaches aimed at differentiating these lesions
from other abnormal protein aggregates. As a result, immuno-
histochemical identiﬁcation has been limited to a subset of
proteins classically associated with neurodegeneration, including
β-amyloid, α-synuclein, tau, and more recently, TDP-43 and FUS
(Okamoto et al., 1991; Mackenzie et al., 2009). The combination
of LCM and LC–MS/MS has been successfully applied in the
proteomic characterization of multiple neurodegenerative disease
aggregates, including amyloid plaques (Liao et al., 2004), neuroﬁb-
rillary tangles (Wang et al., 2005), and Lewy bodies (Leverenz et al.,
2007). However, in contrast with the capture of amyloid plaques
(Liao et al., 2004), where 2000 aggregates (50–100μm in diam-
eter) were speciﬁcally microdissected from four cortical sections,
each FTLD-U section contained <50 much smaller inclusions.
The small size of these inclusions, typically 1–8μm in diameter
(Okamoto et al., 1991), and their relatively sparse distribution
rendered their direct capture and analysis impractical.
Since direct comparison of inclusion-containing dentate gran-
ule cells with adjacent unaffected granule cells was technically
impossible,we performedmore global comparisons between inde-
pendent pairs of FTLD-U and control cases.We employed a label-
free quantitative proteomics approach to characterize dentate
granule cells microdissected from FTLD-U hippocampal sections.
Only a small proportion of the ﬁnal lysate extracted from the LCM
caps consisted of aggregating proteins, and our approach identi-
ﬁes mainly non-aggregated proteins whose expression is altered
in FTLD-U dentate granule cells. Analysis of three independent
FTLD-U and control sample comparisons resulted in the identiﬁ-
cation of 1252 proteins, of which 73 were signiﬁcantly altered in
FTLD-U. Several of the identiﬁed proteins have been previously
implicated in known pathogenic pathways in FTLD-U or ALS,
including VCP (Gitcho et al., 2009) which demonstrated enrich-
ment of ∼1.3-fold. Moreover, TDP-43, a known component of
ubiquitin-immunoreactive inclusions, was signiﬁcantly enriched
in FTLD-U samples compared with controls. Identiﬁcation of
these established proteins serves to validate our experimental
strategy.
Mass spectrometry is a rapid and sensitive method for the
identiﬁcation of critical proteins in neurodegenerative diseases.
Our MS ﬁndings are highly consistent with global alterations in
protein levels in FTLD-U, but the initial proteins targeted for addi-
tional immunohistochemical analysis didnot localize toubiquitin-
immunoreactive inclusions.While speciﬁc association of a protein
with pathological lesions offers the most straightforward evidence
for involvement in disease, this approach is inherently limited
by the fact that accumulated inclusions in autopsy specimens
may only reveal end-stage pathology resulting from many years
of disease. Several proteins have been shown to play important
roles in the pathogenesis of FTLD-U despite failing to localize
within inclusion bodies. These include progranulin (Baker et al.,
2006; Cruts et al., 2006) and CHMP2B (Skibinski et al., 2005),
both of which were shown to play critical genetic roles in the
disease process. To our knowledge, this study provides the ﬁrst
unbiased proteomic analysis identifying a list of candidate pro-
teins with increased expression in the FTLD-U hippocampus. The
altered level of expression in FTLD-U suggests that some of our 73
candidate proteins contribute to disease pathogenesis, and addi-
tional case–control comparisons may help further delineate those
proteins with consistent change in disease tissues. Moreover, the
identiﬁcation of proteins in several pathways previously impli-
cated in other neurodegenerative diseases, including metabolism
and oxidative stress, protein degradation, and components of the
cytoskeleton, suggest that additional validation of proteins in our
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Table 2 | Proteins enriched in FTLD-U dentate granule cells.
GenBank™ Protein name Average Average Total peptides
accession log2 fold
number ratio1 change
Comparison 1 Comparison 2 Comparison 3
NP_663786.1 Septin 3 3.33 10.08 1 2 1
NP_002788.1 Proteasome beta 5 subunit 2.72 6.59 2 1
NP_115921.1 Fibronectin type III domain containing 1 2.56 5.90 1 1
NP_001145.1 Annexin 5 2.25 4.76 11 4 5
NP_058431.2 v-crk sarcoma virus CT10 oncogene homolog 2.19 4.56 1 1
NP_000137.2 Ferritin, light polypeptide 2.18 4.53 2 1 1
NP_000996.2 Ribosomal protein S3 1.95 3.87 8 1 4
NP_002130.2 RNA binding motif protein, X-linked 1.95 3.86 3 2
NP_005653.3 Voltage-dependent anion channel 3 1.92 3.78 6 4 2
NP_004243.1 Solute carrier family 9 (sodium/hydrogen
exchanger)
1.81 3.49 2 1
NP_444505.1 Ribosomal protein P0 1.71 3.26 4 1 1
NP_808592.1 N -acylsphingosine amidohydrolase (acid
ceramidase) 1
1.64 3.12 2 1
NP_112738.1 Heterogeneous nuclear ribonucleoprotein D 1.61 3.05 2 1
NP_524149.1 Smooth muscle and non-muscle myosin alkali
light chain
1.35 2.55 2 1
NP_000399.1 Glycerol-3-phosphate dehydrogenase 2
(mitochondrial)
1.31 2.48 1 1
NP_009204.1 Prohibitin 2 1.27 2.41 9 8 5
NP_005309.1 H1 histone family, member 0 1.26 2.39 1 2
NP_005134.1 Haptoglobin 1.26 2.39 3 5
NP_060921.2 Centromere protein J 1.23 2.34 1 1
NP_003320.2 Thioredoxin 1.18 2.27 3 1 2
NP_000524.3 Proteolipid protein 1 isoform 1 1.18 2.27 2 2
NP_002956.1 S100 calcium-binding protein A9 1.14 2.20 5 1
NP_036246.1 Caspase 14 precursor 1.13 2.19 1 2
NP_000468.1 Albumin precursor 1.12 2.18 12 6 12
NP_005304.3 Protein disulﬁde isomerase-associated 3 1.09 2.12 10 3 5
NP_000467.1 Adenylate kinase 1 1.08 2.11 4 4 2
NP_942599.1 RAB6A, member RAS oncogene family 1.07 2.10 3 1 2
NP_001958.2 Eukaryotic translation initiation factor 4A 1.04 2.05 1 3
NP_000687.2 Aldehyde dehydrogenase 9A1 1.03 2.03 2 1
NP_002046.1 Glial ﬁbrillary acidic protein 1.00 2.00 35 9 27
NP_000282.1 Phosphoglycerate kinase 1 0.94 1.92 11 5 7
NP_002435.1 Moesin 0.94 1.91 2 2
NP_478059.1 Phosphoserine aminotransferase 0.93 1.90 6 5 1
NP_002842.1 Protein tyrosine phosphatase, receptor-type, Z
polypeptide 1
0.88 1.84 6 2 1
NP_055581.2 Secernin 1 0.86 1.81 1 1
NP_002703.1 Protein phosphatase 1, regulatory subunit 7 0.84 1.79 2 1
NP_002783.1 Proteasome alpha 7 subunit 0.84 1.79 3 1
NP_066270.1 Ubiquitous mitochondrial creatine kinase
precursor
0.83 1.78 5 4 4
NP_003312.3 Tu translation elongation factor, mitochondrial 0.83 1.77 3 1 1
NP_001814.2 Brain creatine kinase 0.82 1.76 8 9 13
NP_002291.1 Lactate dehydrogenase B 0.79 1.73 10 7 8
NP_078974.1 Mitochondrial glutamate carrier 1 0.78 1.72 3 2 3
NP_443100.1 Immunoglobulin superfamily, member 8 0.77 1.71 3 1
(Continued)
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Table 2 | Continued
GenBank™ Protein name Average Average Total peptides
accession log2 fold
number ratio1 change
Comparison 1 Comparison 2 Comparison 3
NP_003841.1 Succinate–CoA ligase, ADP-forming, beta
subunit
0.76 1.69 2 1
NP_001011553.1 Septin 7 (cell division cycle 10) 0.74 1.67 6 1 2
NP_000117.1 Electron transfer ﬂavoprotein, alpha
polypeptide
0.73 1.66 4 2
NP_066268.1 Guanine nucleotide binding protein, alpha
activating polypeptide O
0.73 1.65 8 8 6
NP_006363.3 Synaptotagmin binding, cytoplasmic RNA
interacting protein
0.72 1.65 1 2
NP_055363.1 Tropomodulin 2 (neuronal) 0.71 1.63 4 2
NP_061322.2 Matrin 3 0.70 1.62 2 2
NP_004376.2 Chondroitin sulfate proteoglycan 2 (versican) 0.70 1.62 5 2 4
NP_003356.2 Ubiquinol–cytochrome c reductase core
protein I
0.68 1.60 3 3
NP_149124.2 2′,3′-Cyclic nucleotide 3′ phosphodiesterase 0.64 1.56 8 6 10
NP_031401.1 TAR–DNA binding protein 0.64 1.55 1 1
1Average of protein change across all three FTLD-U/control comparisons.
Table 3 | Proteins decreased in FTLD-U dentate granule cells.
GenBank™ Protein name Average Average Total peptides
accession number log2 ratio1 fold change
Comparison 1 Comparison 2 Comparison 3
NP_997637.1 cAMP-dependent protein kinase −2.67 −6.34 1 1
NP_004246.1 Cytochrome c oxidase subunit Va −1.69 −3.22 2 1
NP_077718.2 NADH–ubiquinone oxidoreductase
Fe−S protein 7
−1.59 −3.01 1 1
NP_072045.1 Ribosomal protein S18 −1.50 −2.83 4 2
NP_002796.4 Proteasome 26S ATPase −1.10 −2.14 1 1
NP_000972.1 Ribosomal protein L19 −1.06 −2.08 2 1
NP_996734.1 Reticulon 1 −1.03 −2.04 3 2
NP_006658.1 Progesterone receptor membrane
component 1
−0.99 −1.99 4 2
NP_000628.2 Glutathione reductase −0.98 −1.97 1 1
NP_006377.2 DEAD box polypeptide 17 −0.98 −1.97 2 1
NP_003008.1 Splicing factor, arginine/serine-rich 3 −0.92 −1.89 2 2
AP_000642.1 Cytochrome c oxidase subunit II −0.83 −1.78 4 5 3
NP_061820.1 Cytochrome c −0.82 −1.77 4 1
NP_001013.1 Ribosomal protein S19 −0.79 −1.73 3 1
NP_733936.1 Aldehyde dehydrogenase 5A1
precursor
−0.79 −1.72 4 1
NP_036192.1 Dynamin 1-like protein −0.78 −1.71 1 2
NP_001027392.1 Syntaxin binding protein 1 −0.72 −1.65 5 6
NP_004823.1 Glutathione-S-transferase omega 1 −0.71 −1.64 1 1
NP 613075.1 H2A histone family, memberY −0.63 −1.54 2 1
1Average of protein change across all three FTLD-U/control comparisons.
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FIGURE 4 | Examination of LCM proteomic candidates by
immunohistochemistry. Representative staining of (A)TDP-43, (B)
Ubiquitin, (C) Septin 3, and (D) Septin 7 in hippocampal sections from FTLD-U
(left) or control (right). While inclusions are apparent with both TDP-43 and
ubiquitin immunohistochemistry (arrows), these bodies are not identiﬁed by
Septin 3 and Septin 7.
FIGURE 5 | Immunoblots of septin 3 and septin 7 confirm proteomic
findings. Frontal cortex samples from two AD, two control, and four FTLD-U
cases were sequentially extracted with RIPA buffer (RIPA soluble) and 8M
urea (detergent-insoluble). Both soluble and insoluble fractions were
immunoblotted with antibodies to septin 3 (top panel) or septin 7 (middle
panel). Notably, septin 3 is enriched in the soluble but not the insoluble
fractions. To ensure equal loading and complete transfer of proteins from the
gel, membranes were reversibly stained with Ponceau S (bottom panel).
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list may be warranted. Their role in FTLD-U and their potential
utility as biomarkers of the disease deserves further study.
ACKNOWLEDGMENTS
We thank Dr. Michael Iuvone for technical help with laser
capture microdissection and Craig J. Heilman for help in the
selection of antibodies. This work was supported by NIH grant
P50 AG025688, P30 NS055077, and NIH training grants F30
NS057902 to Yair M. Gozal and T32 NS007480 to Eric B.
Dammer. The funders had no role in study design, data col-
lection and analysis, decision to publish, or preparation of the
manuscript.
REFERENCES
Baker, M., Mackenzie, I. R., Pickering-
Brown, S. M., Gass, J., Rademak-
ers, R., Lindholm, C., Snowden,
J., Adamson, J., Sadovnick, A. D.,
Rollinson, S., Cannon,A.,Dwosh, E.,
Neary, D., Melquist, S., Richardson,
A.,Dickson,D.,Berger,Z.,Eriksen, J.,
Robinson, T., Zehr, C., Dickey, C. A.,
Crook, R., McGowan, E., Mann, D.,
Boeve, B., Feldman, H., and Hutton,
M. (2006).Mutations in progranulin
cause tau-negative frontotemporal
dementia linked to chromosome 17.
Nature 442, 916–919.
Bonner, R. F., Emmert-Buck, M., Cole,
K., Pohida, T., Chuaqui, R., Gold-
stein, S., and Liotta, L. A. (1997).
Laser capture microdissection: mol-
ecular analysis of tissue. Science 278,
1481,1483.
Buratti, E., Dork, T., Zuccato, E., Pagani,
F., Romano, M., and Baralle, F. E.
(2001). Nuclear factor TDP-43 and
SR proteins promote in vitro and in
vivo CFTR exon 9 skipping. EMBO
J. 20, 1774–1784.
Cairns, N. J., Bigio, E. H., Mackenzie, I.
R., Neumann,M., Lee,V. M., Hatan-
paa, K. J.,White, C. L. III, Schneider,
J. A., Grinberg, L. T., Halliday, G.,
Duyckaerts, C., Lowe, J. S., Holm, I.
E., Tolnay, M., Okamoto, K., Yokoo,
H.,Murayama, S.,Woulfe, J.,Munoz,
D. G., Dickson, D. W., Ince, P. G.,
Trojanowski, J. Q., and Mann, D.
M. (2007). Neuropathologic diag-
nostic and nosologic criteria for
frontotemporal lobar degeneration:
consensus of the Consortium for
Frontotemporal Lobar Degenera-
tion. Acta Neuropathol. 114, 5–22.
Cheng, D., Hoogenraad, C. C., Rush, J.,
Ramm, E., Schlager, M. A., Duong,
D. M., Xu, P., Rukshan, S., Han-
felt, J., Nakagawa, T., Sheng, M.,
and Peng, J. (2006). Relative and
absolute quantiﬁcation of postsy-
naptic density proteome isolated
from rat forebrain and cerebellum.
Mol. Cell. Proteomics 5, 1158–1170.
Cruts, M., Gijselinck, I., van der Zee, J.,
Engelborghs, S., Wils, H., Pirici, D.,
Rademakers, R., Vandenberghe, R.,
Dermaut, B.,Martin, J. J., van Duijn,
C., Peeters, K., Sciot, R., Santens, P.,
De Pooter, T.,Mattheijssens,M.,Van
den Broeck, M., Cuijt, I., Vennekens,
K., De Deyn, P. P., Kumar-Singh, S.,
and Van Broeckhoven, C. (2006).
Null mutations in progranulin
cause ubiquitin-positive fron-
totemporal dementia linked to
chromosome 17q21. Nature 442,
920–924.
Dickson, D. W. (1998). Pick’s disease: a
modern approach. Brain Pathol. 8,
339–354.
Emmert-Buck, M. R., Bonner, R. F.,
Smith, P. D., Chuaqui, R. F., Zhuang,
Z., Goldstein, S. R., Weiss, R. A.,
and Liotta, L. A. (1996). Laser cap-
ture microdissection. Science 274,
998–1001.
Eng, J., McCormack, A. L., and Yates, J.
R. III. (1994). An approach to cor-
relate tandem mass spectral data of
peptides with amino acid sequences
in a protein database. J. Am. Soc.
Mass Spectrom. 5, 976–989.
Eriksen, J. L., and Mackenzie, I. R.
(2008). Progranulin: normal func-
tion and role in neurodegeneration.
J. Neurochem. 104, 287–297.
Forman,M. S., Farmer, J., Johnson, J. K.,
Clark, C. M., Arnold, S. E., Coslett,
H. B., Chatterjee, A., Hurtig, H. I.,
Karlawish, J. H., Rosen, H. J., Van
Deerlin, V., Lee, V. M., Miller, B. L.,
Trojanowski, J. Q., and Grossman,
M. (2006). Frontotemporal demen-
tia: clinicopathological correlations.
Ann. Neurol. 59, 952–962.
Gitcho, M. A., Strider, J., Carter, D.,
Taylor-Reinwald, L., Forman, M.
S., Goate, A. M., and Cairns, N.
J. (2009). VCP mutations causing
frontotemporal lobar degeneration
disrupt localization of TDP-43 and
induce cell death. J. Biol. Chem. 284,
12384–12398.
Goldsworthy, S. M., Stockton, P. S.,
Trempus, C. S., Foley, J. F., and
Maronpot, R. R. (1999). Effects of
ﬁxation on RNA extraction and
ampliﬁcation from laser capture
microdissected tissue. Mol. Car-
cinog. 25, 86–91.
Gozal, Y. M., Cheng, D., Duong, D. M.,
Lah, J. J., Levey, A. I., and Peng,
J. (2006). Merger of laser capture
microdissection andmass spectrom-
etry: a window into the amyloid
plaque proteome. Meth. Enzymol.
412, 77–93.
Gozal, Y. M., Duong, D. M., Gearing,
M., Cheng, D., Hanfelt, J. J., Funder-
burk,C., Peng, J., Lah, J. J., and Levey,
A. I. (2009). Proteomics analysis
reveals novel components in the
detergent-insoluble subproteome in
Alzheimer’s disease. J. Proteome Res.
8, 5069–5079.
Graff-Radford, N. R., and Woodruff, B.
K. (2007). Frontotemporal demen-
tia. Semin. Neurol. 27, 48–57.
Kovari, E., Gold, G., Giannakopoulos,
P., and Bouras, C. (2004). Corti-
cal ubiquitin-positive inclusions in
frontotemporal dementia without
motor neuron disease: a quanti-
tative immunocytochemical study.
Acta Neuropathol. 108, 207–212.
Kumar-Singh, S., andVan Broeckhoven,
C. (2007). Frontotemporal lobar
degeneration: current concepts in
the light of recent advances. Brain
Pathol. 17, 104–114.
Kwiatkowski, T. J. Jr., Bosco, D. A.,
Leclerc, A. L., Tamrazian, E., Van-
derburg, C. R., Russ, C., Davis, A.,
Gilchrist, J., Kasarskis, E. J., Mun-
sat, T., Valdmanis, P., Rouleau, G. A.,
Hosler, B. A., Cortelli, P., de Jong,
P. J., Yoshinaga, Y., Haines, J. L.,
Pericak-Vance,M.A.,Yan, J., Ticozzi,
N., Siddique, T.,McKenna-Yasek, D.,
Sapp, P. C., Horvitz, H. R., Landers,
J. E., and Brown, R. H. Jr. (2009).
Mutations in the FUS/TLS gene
on chromosome 16 cause familial
amyotrophic lateral sclerosis. Science
323, 1205–1208.
Leverenz, J. B.,Umar, I.,Wang,Q.,Mon-
tine, T. J., McMillan, P. J., Tsuang,
D. W., Jin, J., Pan, C., Shin, J., Zhu,
D., and Zhang, J. (2007). Proteomic
identiﬁcation of novel proteins in
cortical lewybodies.BrainPathol.17,
139–145.
Li, X. J., Zhang, H., Ranish, J. A., and
Aebersold, R. (2003). Automated
statistical analysis of protein abun-
dance ratios from data generated by
stable-isotope dilution and tandem
mass spectrometry. Anal. Chem. 75,
6648–6657.
Liao, L., Cheng, D., Wang, J., Duong,
D. M., Losik, T. G., Gearing, M.,
Rees, H. D., Lah, J. J., Levey, A. I.,
and Peng, J. (2004). Proteomic char-
acterization of postmortem amy-
loid plaques isolated by laser capture
microdissection. J. Biol. Chem. 279,
37061–37068.
Litvan, I., Hauw, J. J., Bartko, J. J., Lan-
tos, P. L.,Daniel, S. E.,Horoupian,D.
S., McKee, A., Dickson, D., Bancher,
C., Tabaton, M., Jellinger, K., and
Anderson, D. W. (1996). Validity
and reliability of the preliminary
NINDS neuropathologic criteria for
progressive supranuclear palsy and
related disorders. J. Neuropathol.
Exp. Neurol. 55, 97–105.
Mackenzie, I. R., Neumann, M., Bigio,
E. H., Cairns, N. J., Alafuzoff, I., Kril,
J., Kovacs, G. G., Ghetti, B., Halliday,
G., Holm, I. E., Ince, P. G., Kam-
phorst, W., Revesz, T., Rozemuller,
A. J., Kumar-Singh, S., Akiyama, H.,
Baborie, A., Spina, S., Dickson, D.
W., Trojanowski, J. Q., and Mann,
D. M. (2009). Nomenclature for
neuropathologic subtypes of fron-
totemporal lobar degeneration: con-
sensus recommendations. Acta Neu-
ropathol. 117, 15–18.
Mackenzie, I. R., and Rademakers, R.
(2007). The molecular genetics and
neuropathology of frontotemporal
lobar degeneration: recent develop-
ments. Neurogenetics 8, 237–248.
McKeith, I. G., Dickson, D. W., Lowe,
J., Emre, M., O’Brien J. T., Feld-
man, H., Cummings, J., Duda, J.
E., Lippa, C., Perry, E. K., Aars-
land, D., Arai, H., Ballard, C. G.,
Boeve, B., Burn, D. J., Costa, D.,
Del Ser, T., Dubois, B., Galasko, D.,
Gauthier, S., Goetz, C. G., Gomez-
Tortosa, E., Halliday, G., Hansen, L.
A., Hardy, J., Iwatsubo, T., Kalaria, R.
N., Kaufer,D., Kenny, R. A., Korczyn,
A., Kosaka, K., Lee, V. M., Lees, A.,
Litvan, I., Londos, E., Lopez, O. L.,
Minoshima, S., Mizuno, Y., Molina,
J. A., Mukaetova-Ladinska, E. B.,
Pasquier, F., Perry, R. H., Schulz, J.
B., Trojanowski, J. Q., and Yamada,
M. (2005). Diagnosis and manage-
ment of dementia with Lewy bodies:
third report of theDLBConsortium.
Neurology 65, 1863–1872.
McKhann, G. M., Albert, M. S., Gross-
man, M., Miller, B., Dickson, D.,
and Trojanowski, J. Q. (2001). Clin-
ical and pathological diagnosis of
frontotemporal dementia: report of
theWork Group on Frontotemporal
Dementia and Pick’s Disease. Arch.
Neurol. 58, 1803–1809.
Mirra, S. S., Heyman, A., McKeel, D.,
Sumi, S. M., Crain, B. J., Brown-
lee, L. M., Vogel, F. S., Hughes, J. P.,
van Belle, G., and Berg, L. (1991).
Frontiers in Neurology | Neurodegeneration April 2011 | Volume 2 | Article 24 | 10
Gozal et al. LCM in proteomics of FTLD-U
The Consortium to Establish a
Registry for Alzheimer’s Disease
(CERAD). Part II. Standardization
of the neuropathologic assessment
of Alzheimer’s disease.Neurology 41,
479–486.
Morrison, B. M., Hof, P. R., and Mor-
rison, J. H. (1998). Determinants of
neuronal vulnerability in neurode-
generative diseases. Ann. Neurol. 44,
S32–S44.
Neary, D., Snowden, J., and Mann, D.
(2005). Frontotemporal dementia.
Lancet Neurol. 4, 771–780.
Neumann, M., Sampathu, D. M.,
Kwong, L. K., Truax, A. C., Mic-
senyi, M. C., Chou, T. T., Bruce, J.,
Schuck, T., Grossman, M., Clark, C.
M., McCluskey, L. F., Miller, B. L.,
Masliah, E., Mackenzie, I. R., Feld-
man, H., Feiden, W., Kretzschmar,
H. A., Trojanowski, J. Q., and Lee, V.
M. (2006). Ubiquitinated TDP-43 in
frontotemporal lobar degeneration
and amyotrophic lateral sclerosis.
Science 314, 130–133.
Okamoto, K., Hirai, S., Yamazaki, T.,
Sun, X. Y., and Nakazato, Y. (1991).
New ubiquitin-positive intraneu-
ronal inclusions in the extra-motor
cortices in patients with amy-
otrophic lateral sclerosis. Neurosci.
Lett. 129, 233–236.
Ornstein, D. K., Gillespie, J. W.,
Paweletz, C. P., Duray, P. H., Her-
ring, J., Vocke, C. D., Topalian, S. L.,
Bostwick,D.G., Linehan,W.M.,Pet-
ricoin, E. F. III, and Emmert-Buck,
M. R. (2000). Proteomic analy-
sis of laser capture microdissected
human prostate cancer and in vitro
prostate cell lines. Electrophoresis 21,
2235–2242.
Peng, J., Elias, J. E., Thoreen, C.
C., Licklider, L. J., and Gygi, S.
P. (2003). Evaluation of multidi-
mensional chromatography coupled
with tandem mass spectrometry
(LC/LC-MS/MS) for large-scale pro-
tein analysis: the yeast proteome. J.
Proteome Res. 2, 43–50.
Rollinson, S., Rizzu, P., Sikkink, S.,
Baker, M., Halliwell, N., Snowden,
J., Traynor, B. J., Ruano, D., Cairns,
N., Rohrer, J. D., Mead, S., Collinge,
J., Rossor, M., Akay, E., Guerreiro,
R., Rademakers, R., Morrison, K.
E., Pastor, P., Alonso, E., Martinez-
Lage, P., Graff-Radford, N., Neary,
D., Heutink, P., Mann, D. M., Van
Swieten, J., and Pickering-Brown, S.
M. (2009).Ubiquitin associated pro-
tein 1 is a risk factor for frontotem-
poral lobar degeneration. Neurobiol.
Aging 30, 656–665.
Seyfried, N. T., Gozal, Y. M., Dammer,
E. B., Xia, Q., Duong, D. M., Cheng,
D., Lah, J. J., Levey, A. I., and
Peng, J. (2010). Multiplex SILAC
analysis of a cellular TDP-43 pro-
teinopathy model reveals protein
inclusions associated with SUMOy-
lation and diverse polyubiquitin
chains. Mol. Cell. Proteomics 9,
705–718.
Shevchenko, A., Wilm, M., Vorm, O.,
andMann,M. (1996). Mass spectro-
metric sequencing of proteins silver-
stained polyacrylamide gels. Anal.
Chem. 68, 850–858.
Simone, N. L., Bonner, R. F., Gille-
spie, J. W., Emmert-Buck, M. R.,
and Liotta, L. A. (1998). Laser-
capture microdissection: opening
the microscopic frontier to mol-
ecular analysis. Trends Genet. 14,
272–276.
Skibinski, G., Parkinson, N. J., Brown,
J. M., Chakrabarti, L., Lloyd, S.
L., Hummerich, H., Nielsen, J.
E., Hodges, J. R., Spillantini, M.
G., Thusgaard, T., Brandner, S.,
Brun, A., Rossor, M. N., Gade,
A., Johannsen, P., Sorensen, S. A.,
Gydesen, S., Fisher, E. M., and
Collinge, J. (2005). Mutations in the
endosomal ESCRTIII-complex sub-
unit CHMP2B in frontotemporal
dementia. Nat. Genet. 37, 806–808.
Snowden, J., Neary, D., and Mann,
D. (2007). Frontotemporal
lobar degeneration: clinical and
pathological relationships. Acta
Neuropathol. 114, 31–38.
Tan, A. Y., and Manley, J. L. (2010).
TLS inhibits RNA polymerase III
transcription. Mol. Cell. Biol. 30,
186–196.
The National Institute on Aging, and
Reagan Institute Working Group
on Diagnostic Criteria for the
Neuropathological Assessment of
Alzheimer’sDisease (1997). Consen-
sus recommendations for the post-
mortem diagnosis of Alzheimer’s
disease. Neurobiol. Aging 18, S1–S2.
Trojanowski, J. Q., and Dickson, D.
(2001). Update on the neuropatho-
logical diagnosis of frontotempo-
ral dementias. J. Neuropathol. Exp.
Neurol. 60, 1123–1126.
Vance, C., Rogelj, B., Hortobagyi, T.,
De Vos, K. J., Nishimura, A. L.,
Sreedharan, J., Hu, X., Smith, B.,
Ruddy,D.,Wright, P.,Ganesalingam,
J., Williams, K. L., Tripathi, V., Al-
Saraj, S., Al-Chalabi, A., Leigh, P.
N., Blair, I. P., Nicholson, G., de
Belleroche, J., Gallo, J. M., Miller, C.
C., and Shaw, C. E. (2009). Muta-
tions in FUS, an RNA processing
protein, cause familial amyotrophic
lateral sclerosis type 6. Science 323,
1208–1211.
Wang, Q., Woltjer, R. L., Cimino,
P. J., Pan, C., Montine, K. S.,
Zhang, J., and Montine, T. J. (2005).
Proteomic analysis of neuroﬁbril-
lary tangles in Alzheimer disease
identiﬁes GAPDH as a detergent-
insoluble paired helical ﬁlament
tau binding protein. FASEB J. 19,
869–871.
Wang, W., Zhou, H., Lin, H., Roy, S.,
Shaler, T. A., Hill, L. R., Norton, S.,
Kumar, P., Anderle, M., and Becker,
C. H. (2003). Quantiﬁcation of pro-
teins and metabolites by mass spec-
trometry without isotopic labeling
or spiked standards. Anal. Chem. 75,
4818–4826.
Watts, G. D., Wymer, J., Kovach,
M. J., Mehta, S. G., Mumm, S.,
Darvish, D., Pestronk, A., Whyte,
M. P., and Kimonis, V. E. (2004).
Inclusion body myopathy associ-
ated with Paget disease of bone
and frontotemporal dementia
is caused by mutant valosin-
containing protein. Nat. Genet. 36,
377–381.
Woulfe, J., Kertesz, A., and Munoz, D.
G. (2001). Frontotemporal dementia
with ubiquitinated cytoplasmic and
intranuclear inclusions. Acta Neu-
ropathol. 102, 94–102.
Yang, L., Embree, L. J., Tsai, S.,
and Hickstein, D. D. (1998).
Oncoprotein TLS interacts with
serine-arginine proteins involved in
RNA splicing. J. Biol. Chem. 273,
27761–27764.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 02 September 2010; accepted:
01 April 2011; published online: 25 April
2011.
Citation: Gozal YM,Dammer EB, Duong
DM, Cheng D, Gearing M, Rees HD,
Peng J, Lah JJ and Levey AI (2011)
Proteomic analysis of hippocampal den-
tate granule cells in frontotemporal lobar
degeneration: application of laser cap-
ture technology. Front. Neur. 2:24. doi:
10.3389/fneur.2011.00024
This article was submitted to Frontiers in
Neurodegeneration, a specialty of Fron-
tiers in Neurology.
Copyright © 2011 Gozal, Dammer,
Duong, Cheng, Gearing, Rees, Peng, Lah
and Levey. This is an open-access arti-
cle subject to a non-exclusive license
between the authors and Frontiers Media
SA, which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and other Frontiers conditions are
complied with.
www.frontiersin.org April 2011 | Volume 2 | Article 24 | 11
